Endovascular Engineering, Inc. ("E2") has secured $42 million in an oversubscribed Series B financing to advance its next generation clot removal technology platform for venous thromboembolism (VTE).

Effective dyspnea evaluation in urgent care requires the usage of a systems-based framework for categorizing the differential ...

In the United States alone, 104 million people are at risk of cardiovascular disease, and in a study of those that experienced a heart attack at age 50 or younger, half were not previously seen as ...

Former NBA All-Star Chris Bosh saw his career end prematurely as a result of blood clots, but Victor Wembanyama is not ...

Expert sommeliers can take a whiff of a glass of wine and tell you a lot about what's in your pinot noir or cabernet ...

"Endovascular Engineering secures $42m for clot removal technology platform" was originally created and published by Medical ...

Think of your loved ones — your family, friends, people you work with, or even the people in your community. Can you name ...

Endovascular Engineering, Inc. (E2) announced it has secured $42 million in oversubscribed Series B financing to advance its n ...

Up to 20% of patients requiring mechanical ventilation will suffer from difficult weaning (the need of more than 7 days of weaning after the first spontaneous breathing trial), which may depend on ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Personalized Care A nurse practitioner with NYU's pulmonary intervention team chronicles the NSCLC patient experience from diagnosis to ...